Immune Evasion by F. tularensis

土拉弗朗西斯菌的免疫逃避

基本信息

  • 批准号:
    7896798
  • 负责人:
  • 金额:
    $ 37.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-22 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of this proposal is to understand the strategies used by F. tularensis to evade the immune response, and to ultimately devise ways to defeat the immune evasion by the bacteria. F. tularensis is a gram-negative, facultative intracellular bacterium. This bacteria require only a very low infective dose via aerosol infection, and has a long lifetime in the environment. Although F. tularensis infection in the US is not highly prevalent, it has the potential to become an important pathogen especially following intentional release. While the immune response to F. tularensis has not been well studied, it does require T cells for clearance of infection and resistance to reinfection. Our preliminary work shows that like many viruses and some bacteria, F. tularensis has evolved multiple strategies for evading the host innate and adaptive immune response. Two of these, the production of PGE2 by infected host cells and the down-regulation of MHC class I on infected cells are the targets for study in this proposal. In this application we propose to understand the genetic and molecular basis for these two forms of immune evasion. Public Health Relevance: The war between hosts and invaders has endured since the rise of the first multicellular organisms. This interaction has been honed to a high level in the relationship between intracellular bacteria and mammals. The main purpose of both the innate and adaptive mammalian immune systems is to avoid the destruction of the host due to bacterial and viral growth. At the same time bacteria and viruses have evolved multiple mechanisms to evade the host immune response. Here we study the mechanism evolved by the intracellular pathogen F. tularensis to modify the host immune response in order to make the bacteria more able to survive and multiply. The study of the interactions of the host with these bacteria will help point out not only the mechanism used by F. tularensis, but also ways in which other pathogens avoid the host immune response. The molecules used will provide important insights into the mechanisms of effective immunity, and provide potential drugable targets for the development of therapeutics, and vaccine adjuvants.
描述(由申请人提供):本提案的目标是了解F。tularensis逃避免疫反应,并最终设计出击败细菌免疫逃避的方法。F.土拉菌是革兰氏阴性的兼性胞内细菌。这种细菌通过气溶胶感染仅需要非常低的感染剂量,并且在环境中具有很长的寿命。虽然F.土拉菌感染在美国并不十分普遍,它有可能成为一种重要的病原体,特别是在故意释放之后。而对F.虽然土拉热还没有得到很好的研究,但它确实需要T细胞来清除感染和抵抗再感染。我们的初步工作表明,像许多病毒和一些细菌一样,F。土拉热已经进化出多种策略来逃避宿主的先天性和适应性免疫应答。其中两个,PGE2的生产受感染的宿主细胞和受感染的细胞上的MHC I类的下调是在这个建议中的研究目标。在这个应用程序中,我们建议了解这两种形式的免疫逃避的遗传和分子基础。公共卫生相关性:自第一个多细胞生物出现以来,宿主和入侵者之间的战争就一直持续着。这种相互作用在细胞内细菌和哺乳动物之间的关系中已经达到了很高的水平。先天性和适应性哺乳动物免疫系统的主要目的是避免由于细菌和病毒生长而对宿主的破坏。与此同时,细菌和病毒已经进化出多种机制来逃避宿主的免疫反应。在这里,我们研究了细胞内病原体F。土拉菌的作用是改变宿主的免疫反应,使细菌更能存活和繁殖。宿主与这些细菌相互作用的研究不仅有助于指出F。土拉热,但也有其他病原体避免宿主免疫反应的方式。所使用的分子将为有效免疫的机制提供重要的见解,并为治疗剂和疫苗佐剂的开发提供潜在的药物靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFREY Allen FRELINGER其他文献

JEFFREY Allen FRELINGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFREY Allen FRELINGER', 18)}}的其他基金

Mechanisms of Colonization and Persistence by Neisseria
奈瑟菌定植和持续存在的机制
  • 批准号:
    9548008
  • 财政年份:
    2017
  • 资助金额:
    $ 37.5万
  • 项目类别:
Route of Infection Shapes Immune Responses to Francisella
感染途径影响弗朗西斯菌的免疫反应
  • 批准号:
    8375875
  • 财政年份:
    2012
  • 资助金额:
    $ 37.5万
  • 项目类别:
Route of Infection Shapes Immune Responses to Francisella
感染途径影响弗朗西斯菌的免疫反应
  • 批准号:
    8234185
  • 财政年份:
    2011
  • 资助金额:
    $ 37.5万
  • 项目类别:
Immune Evasion by F. tularensis
土拉弗朗西斯菌的免疫逃避
  • 批准号:
    7727737
  • 财政年份:
    2009
  • 资助金额:
    $ 37.5万
  • 项目类别:
Immune Evasion by F. tularensis
土拉弗朗西斯菌的免疫逃避
  • 批准号:
    8481501
  • 财政年份:
    2009
  • 资助金额:
    $ 37.5万
  • 项目类别:
Immune Evasion by F. tularensis
土拉弗朗西斯菌的免疫逃避
  • 批准号:
    8286237
  • 财政年份:
    2009
  • 资助金额:
    $ 37.5万
  • 项目类别:
Immune Evasion by F. tularensis
土拉弗朗西斯菌的免疫逃避
  • 批准号:
    8123149
  • 财政年份:
    2009
  • 资助金额:
    $ 37.5万
  • 项目类别:
Route of Infection Shapes Immune Responses to Francisella
感染途径影响弗朗西斯菌的免疫反应
  • 批准号:
    7671889
  • 财政年份:
    2009
  • 资助金额:
    $ 37.5万
  • 项目类别:
Genetics of Host Resistance to Franciscella tularensis in Mice
小鼠对土拉弗朗西斯氏菌宿主抗性的遗传学
  • 批准号:
    7259227
  • 财政年份:
    2007
  • 资助金额:
    $ 37.5万
  • 项目类别:
Genetics of Host Resistance to Franciscella tularensis in Mice
小鼠对土拉弗朗西斯氏菌宿主抗性的遗传学
  • 批准号:
    7479604
  • 财政年份:
    2007
  • 资助金额:
    $ 37.5万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 37.5万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 37.5万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 37.5万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 37.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 37.5万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 37.5万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 37.5万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 37.5万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 37.5万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 37.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了